Aging-associated changes in CD47 arrangement and interaction with thrombospondin-1 on red blood cells visualized by super-resolution imaging. PMID: 32866348
The expression of CD47 and its association with 2,3-DPG levels in stored leuco-reduced blood units. PMID: 30713045
Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPalpha in adult T-cell leukemia/lymphoma. PMID: 32569413
SIRPalpha/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells. PMID: 31207067
Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma. PMID: 33256380
CD47 on artificial structures. PMID: 26298418
CD47 blockade alleviates acute rejection of allogeneic mouse liver transplantation by reducing ischemia/reperfusion injury. PMID: 31884341
Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. PMID: 23101472
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. PMID: 32929084
Just eat it: A review of CD47 and SIRP-alpha antagonism. PMID: 32517874
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. PMID: 22451913
Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. PMID: 31771616
CD47 Protects Synapses from Excess Microglia-Mediated Pruning during Development. PMID: 30308165
Epithelial CD47 is critical for mucosal repair in the murine intestine in vivo. PMID: 31676794
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. PMID: 19632179
Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition. PMID: 32576678
Exosome-SIRPalpha, a CD47 blockade increases cancer cell phagocytosis. PMID: 28086180
The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. PMID: 24215318
The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors. PMID: 31686549
Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRP axis. PMID: 31183992
CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer. PMID: 27411490
CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. PMID: 33389016
The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. PMID: 22310103
CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. PMID: 31689243
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. PMID: 32761423
Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. PMID: 19144521
Thrombospondin-1/CD47 Interaction Regulates Th17 and Treg Differentiation in Psoriasis. PMID: 31214201
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. PMID: 26512116
Monoclonal anti-CD47 interference in red cell and platelet testing. PMID: 30516833
Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade. PMID: 30762908
Chemotherapy induces enrichment of CD47(+)/CD73(+)/PDL1(+) immune evasive triple-negative breast cancer cells. PMID: 29367423
Targeted inhibition of CD47-SIRPalpha requires Fc-FcgammaR interactions to maximize activity in T-cell lymphomas. PMID: 31383641
CD47-signal regulatory protein alpha signaling system and its application to cancer immunotherapy. PMID: 29873856
Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPalpha Interaction as a Potential Cancer Immunotherapy. PMID: 32640189
A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. PMID: 28378740
CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity. PMID: 31852716
TTI-621 (SIRPalphaFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. PMID: 27856600
Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. PMID: 30878596
Durable antitumor responses to CD47 blockade require adaptive immune stimulation. PMID: 27091975
Phagocytosis checkpoints as new targets for cancer immunotherapy. PMID: 31462760
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. PMID: 19632178
Blockade of CD47 or SIRPalpha: a new cancer immunotherapy. PMID: 32799682
Targeting the CD47-SIRPalpha signaling axis: current studies on B-cell lymphoma immunotherapy. PMID: 30226089
Recent Advancements in CD47 Signal Transduction Pathways Involved in Vascular Diseases. PMID: 32733941
CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises. PMID: 29667847
Dysregulated integrin alphaVbeta3 and CD47 signaling promotes joint inflammation, cartilage breakdown, and progression of osteoarthritis. PMID: 31534047
Targeting CD47 in Sezary syndrome with SIRPalphaFc. PMID: 30962222
Is CD47 a potentially promising therapeutic target in cardiovascular diseases? - Role of CD47 in cardiovascular diseases. PMID: 32061866
CD47: a potential immunotherapy target for eliminating cancer cells. PMID: 26830085
CD47 regulates renal tubular epithelial cell self-renewal and proliferation following renal ischemia reperfusion. PMID: 27259369
miR-128 Regulates Tumor Cell CD47 Expression and Promotes Anti-tumor Immunity in Pancreatic Cancer. PMID: 32536914
Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. PMID: 28234345
Identification of Glutaminyl Cyclase isoenzyme isoQC as a regulator of SIRPalpha-CD47 axis. PMID: 31089204
CD47 does not mediate amyloid-beta(1-42) protofibril-stimulated microglial cytokine release. PMID: 25451248
Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation. PMID: 30569825
Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer. PMID: 28351890
Donor CD47 controls T cell alloresponses and is required for tolerance induction following hepatocyte allotransplantation. PMID: 27230788
CD47 signaling regulates the immunosuppressive activity of VEGF in T cells. PMID: 25200950
Role of Erythrocyte CD47 in Intracerebral Hematoma Clearance. PMID: 26732568
CD47(high) expression on CD4 effectors identifies functional long-lived memory T cell progenitors. PMID: 22461697
Blocking CD47 shrinks pancreatic tumors. PMID: 25092731
RRx-001, a downregulator of the CD47- SIRPalpha checkpoint pathway, does not cause anemia or thrombocytopenia. PMID: 33432831
Single-cell RNA sequencing study of retinal immune regulators identified CD47 and CD59a expression in photoreceptors-Implications in subretinal immune regulation. PMID: 32166783
Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy. PMID: 30056566
Macrophage engulfment of a cell or nanoparticle is regulated by unavoidable opsonization, a species-specific 'Marker of Self' CD47, and target physical properties. PMID: 26172292
Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model. PMID: 28337964
CD47 blockade as another immune checkpoint therapy for cancer. PMID: 26444633
Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity. PMID: 32503944
STAT3 inhibition in combination with CD47 blockade inhibits osteosarcoma lung metastasis., PMID:40529368
SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma., PMID:40523887
Multi-tissue single-nucleus RNA-seq reveals cell type-specific regulatory patterns of alternative polyadenylation in pigs., PMID:40523804
Commentary on "Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors"., PMID:40518291
Synaptic pruning genes networks in Alzheimer's disease: correlations with neuropathology and cognitive decline., PMID:40515808
Mechanism of EC-EXOs-Derived THBS3 Targeting CD47 to Regulate BMSCs Differentiation to Ameliorate Bone Loss., PMID:40514348
PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance., PMID:40512837
Drug repurposing of fostamatinib against cancer via potential cytotoxicity and immune checkpoint regulation., PMID:40510356
Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47., PMID:40493414
Sonodynamic therapy-boosted biomimetic nanoplatform targets ferroptosis and CD47 as vulnerabilities for cancer immunotherapy., PMID:40490790
CDH17-targeting CAR-NK cells synergize with CD47 blockade for potent suppression of gastrointestinal cancers., PMID:40487639
Nanoparticle-formulated mRNA encoding engineered multivalent SIRPα-Fc fusion proteins shows robust anti-cancer activity in preclinical models., PMID:40487351
Designed gramicidin-inspired stabilized peptide-based therapeutics to potentiate immunotherapy against aggressive kidney cancer., PMID:40485488
CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth., PMID:40461553
Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer., PMID:40450521
Novel immunotherapy for gastric cancer: targeting the CD47-SIRPα axis., PMID:40437298
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions., PMID:40429716
CD99: A Key Regulator in Immune Response and Tumor Microenvironment., PMID:40427525
CDC34 suppresses macrophage phagocytic activity and predicts poor response to immune checkpoint inhibitor in cancers., PMID:40419082
The cytotoxic effect of quercetin-induced apoptosis on lung metastatic cells from giant cell tumor of bone., PMID:40418557
A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity., PMID:40408355
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy., PMID:40402266
Pan-cancer analysis of phagocytosis regulators in female-specific cancers: a focus on HMGB2., PMID:40396172
Long-term engraftment of human stem and progenitor cells for large-scale production of functional immune cells in engineered pigs., PMID:40394219
USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity., PMID:40379682
Tumor-derived exosomal CCT6A serves as a matchmaker introducing chemokines to tumor-associated macrophages in pancreatic ductal adenocarcinoma., PMID:40374617
CD47 expression in classic follicular lymphoma is associated with event-free survival., PMID:40374148
Immunotherapy of endometrial cancer via CD47 blockade-mediated macrophage phagocytosis., PMID:40371397
Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia., PMID:40369208
The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma., PMID:40358156
EGFR/STAT3 signaling mediates the upregulation of CD47 in HPV-positive cervical cancer by activating p65 and exosome transporter RAB31., PMID:40353624
Dual targeting of ENPP3 and SIRPα with a bispecific antibody enhances macrophage-mediated immunity in renal cell carcinoma., PMID:40349459
Cancer vaccine from intracellularly gelated tumor cells functionalized with CD47 blockage and damage-associated molecular pattern exposure., PMID:40345180
LincNEAT1 Encoded-NEAT1-31 Promotes Phagocytosis by Directly Activating the Aurora-A-PI3K-AKT Pathway., PMID:40344649
Oncolytic viruses targeting CD47: a new road to success?, PMID:40341033
A novel Dual GLP-1/CCK Receptor Agonist Improves Cognitive Performance and Synaptogenesis in the 5 × FAD Alzheimer Mouse Model., PMID:40338455
Refolding of the recombinant IgV domain of CD47 from E. coli for NMR studies., PMID:40334763
Engineered Bacterial Biohybrid-Mediated CD47-SIRPα Blockade and HSP90 Inhibition for Enhanced Immuno-Photothermal Therapy., PMID:40331355
Nanobody-Based PET Imaging of CD47 Expression in Thyroid Carcinoma., PMID:40326602
[Crosstalk and the progression of hepatocellular carcinoma]., PMID:40326070
Development of a high-throughput TR-FRET assay to identify inhibitors of the FAK-paxillin protein-protein interaction., PMID:40318755
TSP-1-CD47-integrin α4β1 axis drives T cell infiltration and synovial inflammation in rheumatoid arthritis., PMID:40308591
CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation., PMID:40307254
Cisplatin reduces immunosuppression caused by tumor-associated macrophages through downregulating CD47-SIRPα signaling in glioblastoma., PMID:40300658
Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells., PMID:40296909
Phagocytosis-Activating Nanocomplex Orchestrates Macrophage-Mediated Cancer Immunotherapy., PMID:40289887
N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan., PMID:40289109
Multi-Omics Analysis of the Immune Effect of the Engineered Exosome Drug Delivery System in Inducing Macrophage Apoptosis., PMID:40284489
Innate immune checkpoint SIRPα/CD47 blockade ameliorates silica-induced pulmonary fibrosis by modulating macrophage immunity., PMID:40279943
CD47-blocking antibody confers metabolic benefits against obesity., PMID:40267910
For research use only. Not for human or drug use.
